DalCor Pharmaceuticals is a biotechnology company focused on developing precision medicine for cardiovascular diseases. Founded in 2015 and headquartered in Montreal, Canada, the company aims to customize treatments based on patients' genetic profiles. Its lead product, dalcetrapib, is a cholesterol ester transfer protein (CETP) inhibitor designed to reduce cardiovascular events in patients with a specific genetic marker in the ADCY9 gene. Clinical studies indicate that individuals with acute coronary syndrome who possess this genetic variant experience significantly fewer cardiovascular events when treated with dalcetrapib compared to placebo. DalCor has obtained a worldwide exclusive license from Roche for dalcetrapib and the associated ADCY9 genetic marker, underscoring its commitment to leveraging pharmacogenomics for enhanced patient outcomes. The company also maintains operational offices in the United States, Switzerland, and the United Kingdom.